A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets-Reference-Cited by-同舟云学术

A Multi-centric Bioequivalence Trial in Ph+ Chronic Myeloid Leukemia Patients to Assess Bioequivalence and Safety Evaluation of Generic Imatinib Mesylate 400 mg Tablets

Published:2016-07-15 Issue:3 Volume:48 Page:1120-1129
ISSN:1598-2998
Container-title:Cancer Research and Treatment
language:en
Short-container-title:Cancer Res Treat

Author:

Arora Rachna,Sharma Manju,Monif Tausif,Iyer Sunil

Publisher

Korean Cancer Association

Subject

Cancer Research,Oncology

Link

http://e-crt.org/upload/pdf/crt-2015-436.pdf

Reference24 articles.

1. RTK mutations and human syndromes: when good receptors turn bad

2. Targeted Drugs in Chronic Myeloid Leukemia

3. Translation of the Philadelphia chromosome into therapy for CML

4. The Biology of Chronic Myeloid Leukemia

5. Chronic myelogenous leukaemia - new therapeutic principles

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Drug Monitoring of Imatinib and N‐Desmethyl Imatinib in Chronic Myeloid Leukemia Patients Using LC‐MS/MS in a Cohort Study;The Journal of Clinical Pharmacology;2023-09

2. Challenges in Chronic Myeloid Leukemia Management in South America;Current Hematologic Malignancy Reports;2021-10

3. Current evidence on the efficacy and safety of generic imatinib in CML and the impact of generics on health care costs;Blood Advances;2021-09-03

4. Use of generic imatinib as first-line treatment in patients with chronic myeloid leukemia (CML): the GIMS (Glivec to Imatinib Switch) study;BLOOD RESEARCH;2020-09-30

5. Computational Approaches in Preclinical Studies on Drug Discovery and Development;Frontiers in Chemistry;2020-09-11